trastuzumab and pertuzumab as maintenance therapy for metastatic HER2+ breast cancer (HER2CLIMB-05)
People with metastatic HER2+ breast cancer are asked to participate in a research study being conducted by Montefiore Medical Center.
You may be eligible to participate in this study if you:
- Are a male or female at least 18 years of age
- Have centrally confirmed HER2+ breast carcinoma
- Have unresectable locally advanced or metastatic disease
- Have received 4-8 cycles (21-day cycles) of previous treatment with trastuzumab, pertuzumab, and taxane as first-line therapy for advanced HER2+ breast cancer with no evidence of disease progression
- Have adequate baseline hematologic parameters
- Have adequate hepatic function
You may NOT participate in this study if you:
- Are unable for any reason to undergo contrast MRI of the brain
- Have a history of allergic reactions to trastuzumab, pertuzumab, or compounds chemically or biologically similar to tucatinib
- Have inability to swallow pills
- Have known immunodeficiency virus (HIV) infection or are positive for Hepatitis B
- Have current conditions of symptomatic congestive heart failure, unstable angina pectoris, uncontrolled hypertension, or cardiac arrhythmia or history of myocardial infarction
- Have any untreated brain lesion
- Are pregnant, breastfeeding, or planning a pregnancy
Contact Information
Ana Bernal Guarin, Study Coordinator
1695 Eastchester Road, Rm 503 Bronx, NY 10461
Phone: (718) 405-8428
Email: abernal@montefiore.org
21-06-336